Curated News
By: NewsRamp Editorial Staff
June 03, 2026

Onco-Innovations Hits Key Manufacturing Milestone for Cancer Drug ONC010

Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • Onco-Innovations advances kilogram-scale B4 production for ONC010, strengthening its position in cancer drug development.
  • Onco-Innovations produced 952 grams of B4 precursor via Dalton Pharma collaboration, supporting GMP production and clinical trials.
  • Onco-Innovations' scalable manufacturing of ONC010 brings potential PNKP inhibitor therapy closer to cancer patients.
  • Onco-Innovations also hired IBN for market awareness, using an unused US$80,000 balance from a prior engagement.

Impact - Why it Matters

This milestone is significant because it brings Onco-Innovations' lead candidate ONC010 closer to clinical trials and eventual approval. Scalable manufacturing of the B4 precursor is a critical step in ensuring that the drug can be produced in sufficient quantities for future studies and, ultimately, for patients. For investors, this progress signals that the company is moving its pipeline forward, potentially increasing the value of its technology. For patients, particularly those with solid tumors, ONC010 represents a novel approach to cancer treatment, and this advancement brings hope for a new therapeutic option.

Summary

Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) has reached a key manufacturing milestone for its lead drug candidate, ONC010. The company announced the successful scale-up of kilogram-scale production of the B4 precursor component, a critical building block for ONC010, which is a nanoparticle-formulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor targeting solid tumors. This work was carried out in collaboration with Dalton Pharma Services, resulting in the production and isolation of approximately 952 grams of B4 material. This achievement supports future formulation development, GMP production, and planned clinical studies, strengthening Onco-Innovations' integrated development strategy and paving the way for a scalable production process for clinical supply.

In addition to the manufacturing progress, Onco-Innovations has engaged InvestorBrandNetwork (“IBN”) to provide market awareness, corporate communications, and digital media services through September 30, 2026, or until budget exhaustion. The company will pay IBN an aggregate cash fee of US$76,500 for these services and intends to apply an unused US$80,000 balance from a prior market awareness engagement toward the consideration. This move underscores the company's commitment to enhancing its visibility and communication with investors and the broader market.

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Its mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumors. For more information, visit the company’s website at https://oncoinnovations.com/. The full press release can be accessed at https://ibn.fm/BbWHd.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Onco-Innovations Hits Key Manufacturing Milestone for Cancer Drug ONC010

blockchain registration record for this content.